GlassScriptPhysician profile
Oktai Mamedov
NPI 1518152347
$61,820.00
in general payments reported to CMS, 2019-2025
22 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $433 · 2021: $509 · 2022: $6,978 · 2023: $7,833 · 2024: $26K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $28K · Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Food and Beverage: $5,502 · Travel and Lodging: $1,260 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $27,600.00 |
| Consulting Fee | $13,610.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Food and Beverage | $5,502.39 |
| Travel and Lodging | $1,260.05 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $48,725.83 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $8,101.12 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $2,411.85 | 2019-2025 | |
| Axsome Therapeutics, INC. | $705.13 | 2023-2025 | Sunosi |
| Vanda Pharmaceuticals INC. | $350.98 | 2022-2023 | Hetlioz, Fanapt |
| Inspire Medical Systems, INC. | $335.29 | 2024-2025 | Inspire |
| Eisai INC. | $219.45 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $207.18 | 2024-2025 | Dupixent |
| Idorsia Pharmaceuticals US INC | $195.35 | 2023 | Quviviq |
| Genzyme Corporation | $163.07 | 2024 | |
| United Therapeutics Corporation | $76.58 | 2024-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $56.86 | 2025 | Airsupra |
| 3b Medical, INC. | $56.51 | 2025 | Luna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.16 | 2025 | Jascayd, Ofev |
| Resmed Corp | $35.17 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $29.35 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $29.11 | 2021 | |
| Zoll Respicardia, INC. | $19.58 | 2023 | Remede System |
| Lilly USA, LLC | $14.58 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $14.50 | 2025 | Glassia |
| Electromed, INC. | $14.01 | 2025 | Smartvest |
| Arbor Pharmaceuticals, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oktai Mamedov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.